Identification of Genetic, Phenotypic, Clinical, Biological and Histological Factors Differentiating Patients With Ovarian Cancer Who Are Refractory to Platinum-based Therapy From Patients Defined as Long-term Responders to Platinum-based Therapy

This study collects and analyzes genetic, biological, and clinical data from women with ovarian cancer to understand why some patients respond extremely well to standard platinum-based chemotherapy (long-term survivors) while others do not respond at all (refractory patients). **You may be eligible if...** - You are an adult woman treated at the Jean Perrin Center - You have ovarian cancer at any stage that was treated with platinum-based chemotherapy as first-line treatment - You fall into one of two categories: your cancer progressed during first-line chemo (refractory), OR you have had no recurrence for at least 5 years after completing first-line chemo (long-term responder) - You have signed a genetic consent form **You may NOT be eligible if...** - You are a minor - You are pregnant - You are under legal guardianship - You object to the use of your medical data - The hospital does not have your tumor tissue sample available for genetic analysis Talk to your doctor to see if this trial is right for you.